Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Immunohistochemical Diagnosis Of Epithelial Mesothelioma.

N. Ordóñez
Published 1999 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Although it is generally accepted that immunohistochemistry can assist in distinguishing between epithelial mesotheliomas and metastatic adenocarcinomas to the serosal membranes, a great deal of controversy exists regarding not only the practical value of some of the markers currently used, but also which should be included as part of the routine diagnostic panel. Until recently, these panels consisted primarily of antibodies that stained adenocarcinomas but not mesotheliomas. Over the last few years, however, markers that are commonly expressed in mesotheliomas but not in adenocarcinomas have been recognized. The focus of this review is on those markers for which there is an indication that they have a practical use in the diagnosis of mesothelioma. Special emphasis is placed on those which have been most recently recognized.
This paper references
Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel.
R. C. Sosolik (1997)
10.1111/j.1699-0463.1994.tb04873.x
Immunohistochemical reactivity in mesothelioma and adenocarcinoma: A stepwise logistic regression analysis
A. Dejmek (1994)
The diagnostic value of thrombomodulin immunolocalization in serous effusions.
V. Ascoli (1995)
10.1159/000333181
Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
M. Barberis (1997)
10.1007/978-94-009-3299-9_10
Monoclonal Antibodies in Clinical and Experimental Pathology of Lung Cancer
L. D. Leij (1987)
10.1093/AJCP/82.1.15
Diffuse malignant mesothelioma of pleura: diagnostic criteria based on an autopsy study.
V. Adams (1984)
Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations.
D. Frisman (1993)
10.1002/DC.2840100207
Monoclonal antibody Ber‐EP4: Its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens
B. Maguire (1994)
10.1097/00000478-198404000-00004
Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma
J. Holden (1984)
10.1136/jcp.48.7.626
OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.
C. Edwards (1995)
10.1097/00000478-199206000-00007
Immunoreactivity for BER‐EP4 in Adenocarcinomas, Adenomatoid Tumors, and Malignant Mesotheliomas
M. Gaffey (1992)
10.1111/j.1365-2303.1992.tb00051.x
Identification of Malignant Cells In Serous Effusions Using A Panel of Monoclonal Antibodies Ber‐Ep4, Mca‐B‐12 and Ema
J. Stoop (1992)
10.1016/S0046-8177(97)90171-4
Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
A. Han (1997)
10.1097/00000478-199609000-00001
Calretinin: a novel immunocytochemical marker for mesothelioma.
C. Doglioni (1996)
10.1038/bjc.1994.208
Production of endothelin-1 and thrombomodulin by human pancreatic cancer cells.
T. Oikawa (1994)
10.1016/s0169-5002(87)80457-9
The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
C. Szpak (1986)
10.1002/1097-0142(19910201)67:3<655::AID-CNCR2820670322>3.0.CO;2-J
Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma
P. R. Wirth (1991)
10.1016/S0344-0338(11)80008-7
Distinction of mesothelioma from carcinoma in pleural effusions. An immunocytochemical study on routinely processed cytoblock preparations.
L. Kuhlmann (1991)
10.1083/JCB.113.1.207
Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons
T. A. Brown (1991)
10.1097/00000478-199108000-00008
Ber‐EP4 Antibody as a Discriminant in the Differential Diagnosis of Malignant Mesothelioma Versus Adenocarcinoma
K. Sheibani (1991)
10.1016/S0344-0338(11)80900-3
The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma.
A. Grove (1994)
10.1111/j.1365-2559.1995.tb01527.x
A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu‐M1, Ber EP4, Tamm‐Horsfall protein and thrombomodulin
R. Attanoos (1995)
10.1016/0277-5379(84)90043-9
Immunoperoxidase staining on frozen tissue sections as a first screening assay in the preparation of monoclonal antibodies directed against small cell carcinoma of the lung.
L. de Leij (1984)
10.1016/0012-1606(87)90119-9
Spatial and temporal expression pattern of N-cadherin cell adhesion molecules correlated with morphogenetic processes of chicken embryos.
K. Hatta (1987)
10.3109/01913129609016331
Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas.
S. Hammar (1996)
The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance.
G. Blobel (1985)
10.1016/S0046-8177(98)90227-1
Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
N. Ordóñez (1998)
10.1002/IJC.2910570713
SCLC‐cluster‐2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP‐2
L. De Leij (1994)
10.1097/00000478-199712000-00002
The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
N. Ordóñez (1997)
10.1016/S0046-8177(97)90154-4
Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas.
T. Tran (1997)
10.1097/00125480-199609000-00001
The Roles of Immunohistochemistry and Electron Microscopy in Distinguishing Epithelial Mesothelioma of the Pleura from Adenocarcinoma
N. Ordóñez (1996)
10.1097/00125480-199801000-00052
Calretinin: a novel tool for diagnostic immunohistochemistry.
A. D. Dei Tos (1998)
10.1016/S0046-8177(97)90184-2
Expression of E-cadherin and N-cadherin in surface epithelial-stromal tumors of the ovary distinguishes mucinous from serous and endometrioid tumors.
A. Peralta Soler (1997)
10.1007/978-94-009-3299-9
Application of Monoclonal Antibodies in Tumor Pathology
D. Ruiter (1987)
Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.
K. Amin (1995)
10.1159/000333902
Quality control of immunocytochemical staining of effusions using a standardized method of cell processing.
V. Kuenen-Boumeester (1996)
Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
M. T. Friedman (1996)
10.1136/jcp.50.10.859
HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.
A. Kennedy (1997)
10.1046/j.1365-2559.1997.6020829.x
Value of thrombomodulin immunostaining in the diagnosis of mesothelioma
N. Ordóñez (1997)
10.1016/S0140-6736(87)90904-4
ANTIGENS OF SMALL-CELL LUNG CANCER: First International Workshop
R. Souhami (1987)
10.1016/S0065-2776(08)60537-4
CD44 and its interaction with extracellular matrix.
J. Lesley (1993)
10.1111/j.1365-2559.1994.tb00575.x
The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis
B. Skov (1994)
Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma.
C. Gamallo (1993)
10.1046/j.1365-2559.1997.d01-590.x
CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma
R. Attanoos (1997)
Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel.
W. Mccaughey (1991)
Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma.
D. Jordon (1989)
10.1016/0167-5699(89)90040-6
CD44--a molecule involved in leukocyte adherence and T-cell activation.
B. Haynes (1989)
10.1046/j.1365-2559.1997.2150833.x
Anti‐cytokeratin 5/6: a positive marker for epithelioid mesothelioma
J. Clover (1997)
10.1111/j.1365-2559.1996.tb01393.x
Mesothelioma‐binding antibodies: thrombomodulin, OV 632 and HBME‐1 and their use in the diagnosis of malignant mesothelioma
R. Attanoos (1996)
10.1007/BF02890064
Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas
R. Moll (1989)
Molecular cloning and characterization of OB-cadherin, a new member of cadherin family expressed in osteoblasts.
M. Okazaki (1994)
10.1016/0046-8177(90)90036-5
Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases.
M. Wick (1990)
10.1136/jcp.43.3.213
Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial.
U. Latza (1990)
Wilms' tumor suppressor gene expression in rat and human mesothelioma.
C. Walker (1994)
10.1016/S0046-8177(97)90008-3
Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies.
A. Donna (1997)
Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
I. Lee (1986)
Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas--a clinicomorphological study of 158 cases.
A. Vortmeyer (1991)
10.1002/(SICI)1097-0339(199806)18:6<473::AID-DC19>3.0.CO;2-E
Hyaluronate binding probe and CD44 in the differential diagnosis of malignant effusions: Disappointing results in cytology material
A. Filie (1998)
The immunohistochemistry of malignant mesothelioma.
A. Leong (1994)
Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
N. Ordóñez (1998)
10.1083/JCB.121.3.643
Regulation of E-cadherin-mediated adhesion by muscarinic acetylcholine receptors in small cell lung carcinoma
C. L. Williams (1993)
10.1097/00000478-199810000-00006
Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
N. Ordóñez (1998)
10.1016/0143-4160(93)90089-O
Characterization of a polyclonal antiserum against the purified human recombinant calcium binding protein calretinin.
B. Schwaller (1993)
10.1002/PATH.1711650209
Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma
M. Delahaye (1991)
10.1126/SCIENCE.2006419
Cadherin cell adhesion receptors as a morphogenetic regulator.
M. Takeichi (1991)
10.1046/j.1365-2559.1998.00405.x
A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours
Garcia‐Prats (1998)
10.1016/0046-8177(93)90080-Z
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
R. Brown (1993)
10.1002/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-Z
WT1 MUTATION IN MALIGNANT MESOTHELIOMA AND WT1 IMMUNOREACTIVITY IN RELATION TO p53 AND GROWTH FACTOR RECEPTOR EXPRESSION, CELL‐TYPE TRANSITION, AND PROGNOSIS
S. Kumar-Singh (1997)
Thrombomodulin is a new biological and prognostic marker for breast cancer: an immunohistochemical study.
S. Kim (1997)
10.1002/CNE.903330307
Differential expression of N‐ and R‐cadherin in functional neuronal systems and other structures of the developing chicken brain
C. Redies (1993)
10.1083/JCB.124.1.71
Expression and modulation of CD44 variant isoforms in humans
C. Mackay (1994)
Expression of a 130-kDa mesothelial and ciliated cell Ag (MCp130) in normal and developing human and rat lung and its role as a diagnostic marker for mesotheliomas and tumors of the female reproductive system.
G. Singh (1995)
10.1002/PATH.1711520409
Pleural mesothelioma of epithelial type and pulmonary adenocarcinoma: An ultrastructural and cytochemical comparison
A. Dewar (1987)
10.1046/j.1365-2559.1996.d01-562.x
Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME‐1 expression
A. Bateman (1997)
10.1002/DC.2840110309
Markers for metastatic adenocarcinoma in serous effusion specimens
P. Shield (1994)
10.1002/JSO.2930350107
Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma
J. Lucas (1987)
10.1016/S0046-8177(83)80048-3
Keratin proteins and carcinoembryonic antigen in lung carcinoma: an immunoperoxidase study of fifty-four cases, with ultrastructural correlations.
J. Said (1983)
10.1111/j.1365-2559.1984.tb02395.x
Immunohistological study of malignant diffuse mesotheliomas of the pleura
H. Loosli (1984)
10.1006/DBIO.1994.1062
N-cadherin involvement in cardiac myocyte interaction and myofibrillogenesis.
A. Soler (1994)
Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma.
C. L. Collins (1992)
10.1038/bjc.1993.169
The role of the cell-cell adhesion molecule E-cadherin in large bowel tumour cell invasion and metastasis.
A. Kinsella (1993)
10.1016/0014-4827(92)90078-M
Expression of the calcium binding protein calretinin in WiDr cells and its correlation to their cell cycle.
V. Gotzos (1992)
10.1007/BF02889883
Cytokeratins in normal lung and lung carcinomas
G. Blobel (1984)
10.1016/0046-8177(95)90302-X
The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas.
A. Peralta Soler (1995)
10.1016/0092-8674(90)90694-A
CD44 is the principal cell surface receptor for hyaluronate
A. Aruffo (1990)
10.1111/j.1349-7006.1989.tb02336.x
Unstable Expression of E‐Cadherin Adhesion Molecules in Metastatic Ovarian Tumor Cells
M. Hashimoto (1989)
10.1097/00022744-199803000-00003
Differential expression of CD44S and hyaluronic acid in malignant mesotheliomas, adenocarcinomas, and reactive mesothelial hyperplasias
A. Afify (1998)
10.1046/j.1365-2559.1998.00349.x
E‐cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma
Leers (1998)
10.1097/00000478-199810000-00005
Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
N. Ordóñez (1998)



This paper is referenced by
10.1016/S0761-8425(07)91388-1
Apport des puces à ADN dans le diagnostic étiologique des pleurésies : étude de faisabilité
L. Greillier (2007)
10.1002/1096-9896(2000)9999:9999<::AID-PATH772>3.0.CO;2-T
Glyco‐ and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients
K. Kayser (2001)
10.1080/00313020802579250
Diagnosis of epithelial mesothelioma using tree‐based regression analysis and a minimal panel of antibodies
S. Klebe (2009)
10.1007/978-3-319-26587-2_72-1
Hepatic Mesotheliomas and Related Neoplasms
A. Zimmermann (2016)
10.1043/1543-2165(2004)128<107:PQC>2.0.CO;2
Pathologic Quiz Case: A 53-Year-Old Man With Chest Pain and Cough
Frank Schneider (2009)
10.1136/mp.53.3.111
Demystified …
P. Nelson (2000)
Pseudo-Meigs" syndrom
B. Wiatrowska (2000)
10.1007/BF03032608
Poorly differentiated synovial sarcoma: A case report
F. Cappello (2009)
10.1136/jcp.55.9.662
Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies
A. S. Abutaily (2002)
Two Improvements of NMF Used for Tumor Clustering ∗
Zhong-Yuan Zhang (2007)
10.1016/S0003-4975(02)04403-X
Visceral pleura invasion and pleural lavage tumor cytology by lung cancer: a prospective appraisal.
M. Riquet (2003)
10.1111/j.1440-1827.2007.02080.x
Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma
K. Kushitani (2007)
PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA
FATTORI PROGNOSTICI (2012)
10.5772/INTECHOPEN.78307
Pleural Effusions in Lung Cancer: Detection and Treatment
M. Medenica (2018)
10.1053/HP.2000.6552
NCAM (neural cell adhesion molecules) expression in malignant mesotheliomas.
S. Lantuéjoul (2000)
10.1053/HUPA.2001.24329
Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
C. Comin (2001)
10.1046/j.1365-2303.2000.00211.x
Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis
A. Dejmek (2000)
10.1016/j.mehy.2012.11.021
Are oestrogens and genetic predisposition etiologic factors in the development of clear cell carcinoma of the peritoneum?
R. Wuntakal (2013)
10.1046/J.1365-2559.2002.01527.X
The value of 'mesothelium-associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas.
M. Osborn (2002)
10.1007/0-387-32025-3_7
Cytology and surgical pathology of pleural cavities.
C. Y. Castro (2005)
10.1016/S0165-4608(01)00432-0
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma.
A. Sandberg (2001)
10.1309/QHCA-8594-TA7P-0DVQ
An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma.
U. Brockstedt (2000)
10.1046/j.1365-2559.2001.01295.x
Malignant epithelioid mesothelioma: anti‐mesothelial marker expression correlates with histological pattern
R. Attanoos (2001)
Pleural mesothelioma: diagnostic problems and evaluation of prognostic factors.
H. Ismail (2006)
10.1002/cncr.9044
Immunocytochemistry in effusion cytology
P. Fetsch (2001)
10.1080/01913120500313200
Extrathoracic Mesothelial Proliferations and Their Mimics
J. Lloreta-Trull (2006)
10.1097/PAI.0b013e318032cf56
Comparison of Immunohistochemical Markers in the Differential Diagnosis of Adrenocortical Tumors: Immunohistochemical Analysis of Adrenocortical Tumors
H. Zhang (2008)
10.1111/j.1365-2559.2008.03099.x
The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma
R. Attanoos (2008)
10.1016/B978-1-4160-5766-6.00016-9
Chapter 12 – Immunohistology of Lung and Pleural Neoplasms
S. Hammar (2011)
10.1097/01.MP.0000056981.16578.C3
Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma
N. Ordóñez (2003)
Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma.
G. Gordon (2002)
10.1043/0003-9985(2001)125<1598:PASMM>2.0.CO;2
Pulmonary adenocarcinoma simulating malignant mesothelioma.
P. Tang (2001)
See more
Semantic Scholar Logo Some data provided by SemanticScholar